Literature DB >> 8039937

Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine.

A Lee1, M Chen.   

Abstract

In previous studies we found that immunizing mice with a sonicate of Helicobacter felis and adjuvant cholera toxin (CT; 10 micrograms) protected the animals against challenge with viable H. felis. The aim of this study was to determine whether a low dose of CT or its nontoxic B subunit (CTB) was effective as an adjuvant in Helicobacter oral vaccines. Significant protection against viable H. felis challenge was achieved in the animals immunized with H. felis antigen plus the combination of 0.5 microgram of CT and 10 micrograms of CTB (96%), with H. felis antigen plus 0.5 microgram of CT (95%), and with H. felis antigen plus 10 micrograms of CTB (83%). No protective effect was found in the mice immunized with either H. felis antigen alone or adjuvant CTB and CT alone. Twenty-six percent of mice immunized with Helicobacter pylori antigen plus CT (10 micrograms) were protected against H. felis challenge, confirming the value of the model in predicting effects of immunization in humans. The observation that immunity can be induced with a nontoxic adjuvant CTB opens the way for human studies with H. pylori vaccines and is a further step along the road to effective strategies of prevention of gastroduodenal diseases of major world significance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039937      PMCID: PMC303002          DOI: 10.1128/iai.62.8.3594-3597.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

Review 1.  The mucosal immune system: from fundamental concepts to vaccine development.

Authors:  J R McGhee; J Mestecky; M T Dertzbaugh; J H Eldridge; M Hirasawa; H Kiyono
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit.

Authors:  M W Russell; H Y Wu
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

3.  Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin.

Authors:  A D Wilson; C J Clarke; C R Stokes
Journal:  Scand J Immunol       Date:  1990-04       Impact factor: 3.487

Review 4.  A human model of gastric carcinogenesis.

Authors:  P Correa
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701

Review 5.  Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems.

Authors:  J Holmgren; N Lycke; C Czerkinsky
Journal:  Vaccine       Date:  1993-09       Impact factor: 3.641

6.  Gut mucosal, salivary and serum antitoxic and antibacterial antibody responses in Swedes after oral immunization with B subunit-whole cell cholera vaccine.

Authors:  M Jertborn; A M Svennerholm; J Holmgren
Journal:  Int Arch Allergy Appl Immunol       Date:  1984

7.  H-2-unrestricted adjuvant effect of cholera toxin B subunit on murine antibody responses to influenza virus haemagglutinin.

Authors:  Y Hirabayashi; S I Tamura; Y Suzuki; T Nagamine; C Aizawa; K Shimada; T Kurata
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

8.  Helicobacter pylori infection and the risk of gastric carcinoma.

Authors:  J Parsonnet; G D Friedman; D P Vandersteen; Y Chang; J H Vogelman; N Orentreich; R K Sibley
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

9.  Campylobacter pyloridis gastritis I: Detection of urease as a marker of bacterial colonization and gastritis.

Authors:  S L Hazell; T J Borody; A Gal; A Lee
Journal:  Am J Gastroenterol       Date:  1987-04       Impact factor: 10.864

10.  Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.

Authors:  J D Clemens; D A Sack; J R Harris; F Van Loon; J Chakraborty; F Ahmed; M R Rao; M R Khan; M Yunus; N Huda
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

View more
  32 in total

1.  Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice.

Authors:  T Goto; A Nishizono; T Fujioka; J Ikewaki; K Mifune; M Nasu
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis.

Authors:  Xin Li; Jarrod L Erbe; C Virginia Lockatell; David E Johnson; Michael G Jobling; Randall K Holmes; Harry L T Mobley
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

3.  Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa.

Authors:  H A Haeberle; M Kubin; K B Bamford; R Garofalo; D Y Graham; F El-Zaatari; R Karttunen; S E Crowe; V E Reyes; P B Ernst
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

4.  Rapid development of severe hyperplastic gastritis with gastric epithelial dedifferentiation in Helicobacter felis-infected IL-10(-/-) mice.

Authors:  D J Berg; N A Lynch; R G Lynch; D M Lauricella
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

5.  Isolation of "Helicobacter heilmannii" from human tissue.

Authors:  S L Hazell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

Review 6.  Progress towards development of a vaccine for amebiasis.

Authors:  S L Stanley
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

7.  Cure of Helicobacter pylori infection and resolution of gastritis by adoptive transfer of splenocytes in mice.

Authors:  K A Eaton; M E Mefford
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

8.  Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.

Authors:  G Douce; M Fontana; M Pizza; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

9.  Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.

Authors:  T G Blanchard; N Lycke; S J Czinn; J G Nedrud
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

10.  Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis.

Authors:  J Pappo; W D Thomas; Z Kabok; N S Taylor; J C Murphy; J G Fox
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.